The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia
- PMID: 27720198
- PMCID: PMC5675052
- DOI: 10.1016/j.biopsych.2016.07.014
The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia
Abstract
The dopamine hypothesis is the longest standing pathoetiologic theory of schizophrenia. Because it was initially based on indirect evidence and findings in patients with established schizophrenia, it was unclear what role dopamine played in the onset of the disorder. However, recent studies in people at risk of schizophrenia have found elevated striatal dopamine synthesis capacity and increased dopamine release to stress. Furthermore, striatal dopamine changes have been linked to altered cortical function during cognitive tasks, in line with preclinical evidence that a circuit involving cortical projections to the striatum and midbrain may underlie the striatal dopamine changes. Other studies have shown that a number of environmental risk factors for schizophrenia, such as social isolation and childhood trauma, also affect presynaptic dopaminergic function. Advances in preclinical work and genetics have begun to unravel the molecular architecture linking dopamine, psychosis, and psychosocial stress. Included among the many genes associated with risk of schizophrenia are the gene encoding the dopamine D2 receptor and those involved in the upstream regulation of dopaminergic synthesis, through glutamatergic and gamma-aminobutyric acidergic pathways. A number of these pathways are also linked to the stress response. We review these new lines of evidence and present a model of how genes and environmental factors may sensitize the dopamine system so that it is vulnerable to acute stress, leading to progressive dysregulation and the onset of psychosis. Finally, we consider the implications for rational drug development, in particular regionally selective dopaminergic modulation, and the potential of genetic factors to stratify patients.
Keywords: Dopamine; Etiology; Genetics; Neuroimaging; PET; Prodrome; Psychosis; Schizophrenia; Stress.
Copyright © 2016 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Dr Howes and Prof Murray have received investigator-initiated research funding from and/or participated in advisory/ speaker meetings organised by pharmaceutical companies including Astra-Zeneca, Autifony, BMS, Eli Lilly, Jansenn, Lundbeck, Lyden-Delta, Otsuka, Servier, Sunovion, and Roche. Neither they nor their immediate families have been employed by or have holdings/ a financial stake in any biomedical company. Dr McCutcheon and Prof Owen have no potential conflicts of interest.
Figures
References
-
- Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: a review. Schizophr Bull. 1976;2:19–76. - PubMed
-
- Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148:1474–1486. - PubMed
-
- Angrist BM, Gershon S. Biol Psychiatry. Elsevier Science; 1970. The phenomenology of experimentally induced amphetamine psychosis: preliminary observations. - PubMed
-
- Connell P. Amphetamine psychosis. Br Med J. 1957;5018:582.
Publication types
MeSH terms
Substances
Grants and funding
- MR/K013807/1/MRC_/Medical Research Council/United Kingdom
- MC_U120097115/MRC_/Medical Research Council/United Kingdom
- RP-PG-0606-1049/DH_/Department of Health/United Kingdom
- G1100583/MRC_/Medical Research Council/United Kingdom
- G0600972/MRC_/Medical Research Council/United Kingdom
- MR/N026063/1/MRC_/Medical Research Council/United Kingdom
- WT_/Wellcome Trust/United Kingdom
- G0700995/MRC_/Medical Research Council/United Kingdom
- 094849/Z/10/Z/WT_/Wellcome Trust/United Kingdom
- MR/P005748/1/MRC_/Medical Research Council/United Kingdom
- MR/K004867/1/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
